EP1252296A1 - Procede et systeme de determination de parametres d'un protocole d'utilisation differee de cellules immuno-competentes - Google Patents
Procede et systeme de determination de parametres d'un protocole d'utilisation differee de cellules immuno-competentesInfo
- Publication number
- EP1252296A1 EP1252296A1 EP01907656A EP01907656A EP1252296A1 EP 1252296 A1 EP1252296 A1 EP 1252296A1 EP 01907656 A EP01907656 A EP 01907656A EP 01907656 A EP01907656 A EP 01907656A EP 1252296 A1 EP1252296 A1 EP 1252296A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- human
- information
- animal subject
- animal
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H30/00—ICT specially adapted for the handling or processing of medical images
- G16H30/20—ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
Definitions
- the present invention relates to a method for determining parameters of a protocol for the deferred use of immuno-competent cells, as well as an associated method for managing batches of immuno-competent cells, in particular leukocytes, lymphocytes or monocytes, taken on human or animal subjects for deferred use. It also relates to a system for determining parameters of a protocol for deferred use of immunocompetent cells, as well as an associated system for managing batches of immunocompetent cells implementing this system for determining parameters.
- Immunocompetent cells (lymphocytes, phagocytic cells: monocytes, macrophages) play a central role in the immune system.
- lymphocytes store information during life and are the support of the memory of cellular and humoral immunity.
- These immunocompetent cells constitute in a way a library, lymphocyte in particular, which enriches itself during the life, as the individual meets foreign organisms, during viral, parasitic or bacterial infections. It is thanks to it that the body can minimize the impact of infections during life.
- the mechanism of action of cellular immunity is known. Information is stored in particular in the walls of lymphocytes, as shown by the transfer factor and numerous publications. This mechanism also contributes to defense against malignant cells. On the one hand, this memory is partially erased over time, as shown by the need to practice vaccination reminders to maintain effective protection. With respect to humoral immunity, antibody levels decline, rapidly for IgM, more slowly for IgG and IgA.
- Document O9953030 discloses a method for managing batches of immunocompetent cells, comprising, for a given human subject:
- the aim of the present invention is to remedy these drawbacks by proposing a method for determining parameters of a protocol for deferred use of immuno-competent cells from a personal library of a human or animal subject, this personal library accumulating a sum of immune information stored in the immunocompetent cells successively sampled and packaged in the form of batches kept in one or more storage centers, which completely integrates: for human subjects and by extension for animal subjects, the dimension of identity and health status.
- this determination method comprises:
- a storage of said processed information in a cell management database the execution of a sequence of sampling of immunocompetent cells on said human or animal subject being: conditioned by the result of the processing of said characteristic information.
- information characterizing the state of the human or animal subject in particular his state of health and his psychological state, can be processed both to determine the appropriateness of removing immunocompetent cells and for select parameters of a deferred use protocol.
- the information characterizing the state of the su j and animal or human are preferably obtained from a treatment of a collected blood sample from the human or animal subject. They may include bioelectronic information resulting from a processing of respective measurements of the pH, of the Rh2 oxidation-reduction potential and of the p resistivity of the blood previously drawn, according to Vincent's bioelectronic method.
- the information characteristic of the state of the human or animal subject may also include information originating from a processing of images of sensitive crystallization of the blood previously taken from said human or animal subject, and / or information obtained by a capillarity study. elements of the hair system of said human or animal subject.
- the information characteristic of the state of human or animal subjects and the immune information stored in the immunocompetent cells of said human or animal subjects can advantageously be introduced into an expert system used to determine parameters of the deferred use protocols.
- This expert system can be designed to provide an interpretation of information characteristic of the state and immune information of a human or animal subject with respect to a particular gene.
- the processing of information characteristic of the state of a human or animal subject can be arranged to to provide a determination of respective optimal proportions of different immunocompetent cells with a view to their deferred use, and in particular a determination of an optimal ratio between T4 and T8 lymphocytes.
- the method according to the invention When the method according to the invention is implemented in a therapeutic protocol including a reinjection of lymphocytes onto a human or animal subject, the immuno-competent cells previously removed and stored can be subjected to an ex-vivo treatment prior to their reinjection.
- the method according to the invention can also be implemented in a therapeutic protocol including a reinjection of T lymphocytes with specific cytotoxic activity after ex-vivo growth, or in a gene therapy protocol.
- the therapeutic protocol in which the method according to the invention is implemented generally includes a step of verifying the safety of the lymphocytes before reinjection.
- This verification step includes a test of the oxidative stress of the lymphocytes before reinjection, in which these lymphocytes are attacked with free radicals.
- oxidative stress of the lymphocytes before reinjection in which these lymphocytes are attacked with free radicals.
- the oxidative stress test can also be advantageously used to verify different therapeutic paths of ex vivo treatment and their adequacy with respect to the human or animal subject concerned.
- an excessively aggressive lymphocyte product will have a production very high free radicals.
- this test makes it possible to choose the most appropriate treatment for the patient.
- Another particularly promising way of implementing the method according to the invention relates to therapeutic protocols including an ex vivo treatment between lymphocytes and a vaccine before reinjection. It is observed that there is no production of antibodies. It is also possible to provide for an implementation of the method according to the invention in a therapeutic protocol including an ex vivo treatment for allergic desensitization of the lymphocytes before reinjection. The product thus obtained is then mixed with the lymphocytes stored before reinjection.
- the therapeutic protocol in which the method according to the invention is implemented may include a reinjection of lymphocytes by the lymphatic route.
- the objective sought is in particular to reduce the doses to be prescribed for a better tolerance of the patient and a greater speed of reaction.
- the method according to the invention further comprises, before the stage of cryopreservation of a batch of immunocompetent cells, an initial stage of cryogenization of said batch designed to cause the disappearance of the antibodies initially present in said batch.
- This process can also comprise, before any reuse of a batch of immunocompetent cells, a step to verify the disappearance of the antibodies in this batch.
- the latter further comprises, during a sequence of conditioning a batch of immuno-competent cells previously removed, a step of immunomagnetic selection for lympr purified .ocytes or monocytes.
- the determination method according to the invention can advantageously be implemented in a method for managing batches of immunocompetent cells taken from human or animal subjects for deferred use, comprising for each of these human or animal subjects : conditioning and conservation of batches of immunocompetent cells successively sampled, in one or more storage centers, and building up and enriching a personal library of immuno-competent cells from the batches sampled, this personal library accumulating a sum of immune information stored in the immuno-competent cells taken.
- this batch management process further comprises:
- a system for determining parameters of a protocol for the deferred use of immuno-competent cells originating from a personal library of a human or animal subject, this personal library accumulating a sum of immune information stored in the immunocompetent cells successively sampled and packaged in the form of batches kept in one or more storage centers, implementing the method according to the invention.
- means for measuring physical and / or biological characteristics on samples of fluid and / or hair of said human or animal subject before or during the collection of immuno-competent cells means for collecting information characteristic of the state said human or animal subject, said characteristic information resulting from said measurements, means for processing said characteristic information with a view to determining parameters of said deferred use protocol and controlling the execution of a sequence of sampling of immunocompetent cells on said human or animal subject according to the result of the processing of said characteristic information, and
- a system for managing batches of immunocompetent cells belonging to human or animal subjects from which these batches have been removed for deferred use, implementing the batch management method according to the invention, this system comprising for each of these human or animal subjects:
- the system further comprises: means for collecting information characteristic of the state of said enclosuren or animal subject, before or during the collection of immuno-competent cells, and - means for processing said characteristic information in view to determine the parameters of a protocol for deferred use of immunocompetent cells from the personal library of said human or animal subject, and to order the execution of a sequence of sampling of immunocompetent cells on said human or animal subject according to the result ⁇ processing of said information characteristics.
- FIG. 2 is a timing diagram representing the main steps of the management method according to the invention.
- the management method according to the invention generally comprises, with reference to FIG. 1, a first characterization and identification sequence of the state of the human or animal subject, successive sequences of the collection of immuno-competent cells from said subject followed by sequences of cryopreservation and storage of batches of cells, and by one or more sequences of deferred use of conserved cells.
- samples of blood and other fluids and secretions such as saliva or urine are taken from the human or animal subject. Hair samples can also be taken.
- the blood sample can be processed by any suitable biological method to provide information characterizing the effective identity. For example, Vincent's bioelectronic method, which includes a pH measurement, a measurement of the redox potential rH2, and a measurement of the p resistivity of the blood sample, provides an interesting characterization of the state of subject's present health.
- Another useful method of biological evaluation is the processing and interpretation of sensitive blood crystallization images, and provides other characteristic state information regarding the subject's state of health with specific data on various disorders. physiological.
- Characteristic state information provided either by a bioelectronic method or by a sensitive crystallization image method can be corroborated by information processed from a capillarity study carried out on a hair sample.
- a sampling sequence is carried out on the condition that the identity data satisfy physiological criteria to authorize this sequence of sample.
- the blood is collected and separated in order to obtain different cellular components such as lymphocytes or monocytes.
- the different cells obtained by separation are identified, selected, prepared and if necessary processed and divided into a plurality of n batches. These n batches of immunocompetent cells are then conditioned, treated by cryogenics, preserved and stored in various storage sites 1, ..., î, ..., n located to ensure the best level of integrity and security for these batches. cells.
- an immunomagnetic selection process can be used for the purified lymphocytes and monocytes.
- cryo-protectants can be advantageously used during cryopreservation of immunocompetent cells, in particular lymphocytes.
- the immunocompetent cells are preferably stored at a temperature between -80 ° C and -120 ° C. In fact, storage in liquid nitrogen at -196 ° C often poses infrastructure and logistics problems.
- delayed lymphocytes can pose problems if there is conservation of antibodies because over time, there may be on the subject concerned a reaction of its own antibodies and a rejection of these.
- An initial cryogenization phase can be planned, aiming to make the antibodies disappear within a batch of immunocompetent cells. Before any reuse of this batch of cells, a step of verifying the effective disappearance of these antibodies.
- the batches of immunocompetent cells or components of the hematopoietic system can thus be stored over large variable periods of time, which can range from a few days to several decades, provided that appropriate storage of the components of the hematopoietic system over the long term be guaranteed. Furthermore, the principle of not storing all the batches of a patient on the same site contributes significantly to the security of the supply.
- data relating to each elementary step is collected, collected and stored in a cell management database which also receives data from the expert system including the subject's identity data.
- the stored immunocompetent cells belonging to a human or animal subject constitute their personal immune library which is linked to the cell management database which can be located within a management center controlling the plurality of storage sites and one or more several preparation and cryopreservation centers.
- an identification of the personal batches of cells is carried out by consulting (R) the cell management database and receiving (D) from said database identification data associated with an appropriate batch of cells which is transmitted, preferably by express transport, from its site storage to a center specifically equipped for deferred use.
- This center can also be the center from which the initial sample was taken.
- the transmitted batch is then repackaged at room temperature and the immunocompetent cells are cultured and / or subjected to ex-vivo treatment.
- Parameters of a reuse protocol are determined from identity data obtained by interrogating the cell management database and by processing this data in order, for example, to determine an optimal ratio between T4 and T8 lymphocytes for a remission.
- This reuse protocol is then implemented in a reuse process applied to the human or animal subject.
- the management method according to the invention allows the constitution, throughout the life of a human or animal subject, of both a personal cellular library and a personal database containing data resulting from successive characterization sequences. and data generated by using the expert system, with reference to FIG. 2.
- a human or animal subject is subjected to a state characterization and identification process SCo which provides information characterizing the physiological identity and state of health of the subject. If this sequence of characterization leads to a correct evaluation, a sequence of sampling of immunocompetent cells is then carried out at a time TCo on the human or animal subject.
- This state characterization and identification process carries out a screening and biological evaluation operation on the subject concerned.
- Tj another sequence of characterization of state is carried out on the human or animal subject and this sequence leads to data revealing a physiological disorder preventing any removal of cells.
- Therapeutic treatment can then be proposed in order to remedy the diagnosed disorder and another characterization sequence is carried out subsequently at a time Tn until a correct evaluation is obtained authorizing a sequence for the collection of immunocompetent cells.
- the data from successive state characterization sequences are collected and processed in the expert system and stored in the cell management database, while the immunocompetent cells collected enrich the subject's personal cell library.
- a deferred use protocol is determined using data stored in the data base with, for example, optimal proportions between each type of cells.
- the selected immunocompetent cells are then extracted from the personal cell library and, if necessary, processed ex- vivo.
- a reuse process according to the predetermined personal protocol is undertaken at time Tu.
- a patient or subject following this program has a stock of immunocompetent cells or components of the hematopoietic system, which allows him, for example, to provide for successive self-uses, in particular in the form of self- mj ections, over a period of time, with the aim of strengthening the immune system or for the purpose of gene therapy, or for mass use if necessary.
- the management method according to the invention is for example implemented in the form of a software package installed on data processing and management systems, which can be implemented in batch management centers and can be connected to the all of the data processing sites located in cytophyrese, storage and rapid logistics centers.
- the method according to the invention can also find particularly important applications in the field of mass animal production, in particular as an alternative to antibiotic therapy. It can also be used in the field of race horses to provide them with immune protection, as well as for domestic animals as an anti-aging factor and for its action on the immune system.
- the invention is not limited to the examples which have just been described and numerous modifications can be made to these examples without departing from the scope of the invention.
- the means of communication implemented between the various operational and management centers can be of any kind.
- the information collected in the context of the management method according to the invention can advantageously be processed for statistical purposes, with applications in the field of prevention and insurance.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Primary Health Care (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0000804 | 2000-01-21 | ||
FR0000804A FR2804126B1 (fr) | 2000-01-21 | 2000-01-21 | Procede et systeme de gestion de lots de cellules immuno-competentes prelevees sur des sujets humains ou animaux en vue d'utilisations differees |
PCT/FR2001/000193 WO2001053464A1 (fr) | 2000-01-21 | 2001-01-19 | Procede et systeme de determination de parametres d'un protocole d'utilisation differee de cellules immuno-competentes |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1252296A1 true EP1252296A1 (fr) | 2002-10-30 |
Family
ID=8846188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01907656A Withdrawn EP1252296A1 (fr) | 2000-01-21 | 2001-01-19 | Procede et systeme de determination de parametres d'un protocole d'utilisation differee de cellules immuno-competentes |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1252296A1 (fr) |
JP (1) | JP5036945B2 (fr) |
AU (1) | AU2001235570A1 (fr) |
FR (1) | FR2804126B1 (fr) |
WO (1) | WO2001053464A1 (fr) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3421011A1 (de) * | 1984-06-06 | 1985-12-12 | Inge Dr. Schmidt | Individualmedikament |
DE3722647A1 (de) * | 1987-07-09 | 1989-01-19 | Gerhard Ohlenschlaeger | Galenische verwendung eines tripeptids als arzneimittel |
US5004681B1 (en) * | 1987-11-12 | 2000-04-11 | Biocyte Corp | Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood |
US5023785A (en) * | 1987-11-16 | 1991-06-11 | Becton & Dickinson Co. | Hematology - diagnosis apparatus employing expert system technology |
RU2067766C1 (ru) * | 1992-05-15 | 1996-10-10 | Пухова Яна Израйловна | Способ оценки функциональной активности иммунокомпетентных клеток в системе цельной крови |
AU2281395A (en) * | 1994-04-18 | 1995-11-10 | Jacqueline A. Sabal | Method of hair analysis |
NO961221D0 (no) * | 1996-03-26 | 1996-03-26 | Oeystein Fodstad | Fremgangsmåte til å identifisere nye gener assosiert med setepreferert cancer mestastasedannelse |
EP1062515B1 (fr) * | 1998-02-12 | 2009-11-25 | Immunivest Corporation | Methodes et reactifs pour l'isolation rapide et efficace de cellules cancereuses circulantes |
WO1999053030A1 (fr) * | 1998-04-08 | 1999-10-21 | Lefesvre Andre | Procede et systeme de gestion de lots de cellules immuno-competentes en vue d'utilisations differees |
-
2000
- 2000-01-21 FR FR0000804A patent/FR2804126B1/fr not_active Expired - Fee Related
-
2001
- 2001-01-19 WO PCT/FR2001/000193 patent/WO2001053464A1/fr active Application Filing
- 2001-01-19 EP EP01907656A patent/EP1252296A1/fr not_active Withdrawn
- 2001-01-19 JP JP2001553925A patent/JP5036945B2/ja not_active Expired - Lifetime
- 2001-01-19 AU AU2001235570A patent/AU2001235570A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO0153464A1 * |
Also Published As
Publication number | Publication date |
---|---|
FR2804126B1 (fr) | 2005-09-30 |
FR2804126A1 (fr) | 2001-07-27 |
WO2001053464A1 (fr) | 2001-07-26 |
AU2001235570A1 (en) | 2001-07-31 |
JP2003535312A (ja) | 2003-11-25 |
JP5036945B2 (ja) | 2012-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3762001A1 (fr) | Procédure de collecte de selles et procédé de préparation d'un échantillon pour transplantation de microbiote fécal | |
Lingblom et al. | Differences in eosinophil molecular profiles between children and adults with eosinophilic esophagitis | |
Piaia et al. | HLA-typing analysis following allogeneic bone grafting for sinus lifting | |
Agodoa et al. | The appearance of nonlinear deposits of immunoglobulins in Goodpasture's syndrome | |
Yoon et al. | Efficacy of local minocycline agents in treating peri-implantitis: an experimental in vivo study in beagle dogs | |
EP1252296A1 (fr) | Procede et systeme de determination de parametres d'un protocole d'utilisation differee de cellules immuno-competentes | |
Khijmatgar et al. | Residual bone height and new bone formation after maxillary sinus augmentation procedure using biomaterials: a network meta-analysis of clinical trials | |
Berger et al. | A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma® 5% DIF, the next generation of Flebogamma® | |
Smethurst et al. | Rejuvenation of RBCs: validation of a manufacturing method suitable for clinical use | |
Martínez-Flores et al. | The clinical use of cryopreserved human skin allografts for transplantation | |
WO1999053030A1 (fr) | Procede et systeme de gestion de lots de cellules immuno-competentes en vue d'utilisations differees | |
Heldal et al. | Induction with interleukin-2 antagonist for transplantation of kidneys from older deceased donors: an observational study | |
EP1012239A1 (fr) | Procede et systeme de gestion de lots de cellules immuno-competentes en vue d'utilisations differees | |
Verger et al. | Variability of aseptic peritonitis rates in the RDPLF | |
Faine et al. | Guide pour la lutte contre la leptospirose | |
Korsch et al. | Frozen Stored Teeth: Autogenous Dentin as an Alternative Augmentation Material in Dentistry | |
Uchechi et al. | The Re-Addition of Seminal Plasma after Thawing Does Not Improve Buck Sperm Quality Parameters | |
Khishigsuren et al. | Panel reactive antibody responses against influenza vaccination in kidney transplant recipients | |
Ezhil et al. | Saliva as a diagnostic tool: A review. | |
WO1991014181A1 (fr) | Procede de controle de la dilution et de la contamination de solutions a haute dilution | |
Sretenovic et al. | P951: CLINICAL AND LABORATORY CHARACTERISTICS, COURSE AND OUTCOME OF COVID19 INFECTION IN PATIENTS WITH MULTIPLE MYELOMA | |
Blecher et al. | Early diagnosis of thrombotic microangiopathy by paraffin sections of aspirated bone-marrow. | |
Zloczower et al. | The impact of birth weight and gestational age on acute mastoiditis in children | |
FR2518407A1 (fr) | Nouvel antigene pour la recherche de l'immunite toxoplasmique et son procede de preparation | |
Quesnel-Barbet et al. | La géographie de la santé et la planification sanitaire avec le système d'informations médicales |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020819 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17Q | First examination report despatched |
Effective date: 20021213 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SANKHIA INTERNATIONAL INC |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: RAMBAUD, PATRICK |
|
17Q | First examination report despatched |
Effective date: 20021213 |
|
APBK | Appeal reference recorded |
Free format text: ORIGINAL CODE: EPIDOSNREFNE |
|
APBN | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2E |
|
APBR | Date of receipt of statement of grounds of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA3E |
|
APAF | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNE |
|
APBT | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9E |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20130801 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: C12N0005080000 Ipc: C12N0005070000 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: C12N0005080000 Ipc: C12N0005070000 Effective date: 20140602 |